{"product_id":"cancer-consult-expertise-in-clinical-practice-volume-1-isbn-9781119823735","title":"Cancer Consult: Expertise in Clinical Practice, Volume 1","description":"\u003cb\u003eCANCER CONSULT\u003c\/b\u003e \u003cp\u003e\u003cb\u003eNew edition covering the specialties of hematology, oncology and cellular therapy, now in two volumes\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003e\u003ci\u003eCancer Consult: Expertise in Clinical Practice, Volume 1: Solid Tumors \u0026amp; Supportive Care, Second Edition\u003c\/i\u003e includes hundreds of answers to practice-based questions covering the new principles of diagnosis, classification, staging, treatment, and outcomes in the rapidly advancing field of cancer. This textbook series also provides expert guidance in the areas of cancer-related uncertainties and controversies, including experience-based discussions. The book’s smaller size allows for easy access during medical rounds. This volume also includes:  \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eUp-to-date, clinically relevant information on the very latest topics such as molecular techniques, targeted therapies, immunotherapy, cellular therapy and translational cancer research\u003c\/li\u003e \u003cli\u003eSections on head, neck, thoracic, breast, GI, genitourinary, skin, gynecological and hereditary cancers, amongst other topics\u003c\/li\u003e \u003cli\u003eStreamlined, engaging content to make finding information easier and less time consuming for the reader\u003c\/li\u003e \u003cli\u003eConcise and practical expert perspectives that reference key studies\u003c\/li\u003e \u003cli\u003eReferences to the latest NCCN, ESMO, ASCO, and other national guidelines\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWith its powerful focus on pragmatic clinical diagnostic, therapeutic and prognostic approaches, \u003ci\u003eCancer Consult: Expertise in Clinical Practice, Volume 1: Solid Tumors \u0026amp; Supportive Care, Second Edition\u003c\/i\u003e will help keep hematology, oncology and cellular therapy practitioners up-to-date, bridging the gaps between journal and reference literature, conferences, and their existing knowledge base. It also offers clinicians, trainees, and fellows an excellent opportunity to enhance their preparation for the ABIM, hematology and oncology fellowship and recertification exams. \u003c\/p\u003e\u003cp\u003eEditors Volume 1 xi\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVolume 2: Neoplastic Hematology \u0026amp; Cellular Therapy\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEditors xii\u003c\/p\u003e \u003cp\u003eEditor's Biography xiii\u003c\/p\u003e \u003cp\u003ePreface xv\u003c\/p\u003e \u003cp\u003eAcknowledgment xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Central Nervous System 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Central Nervous System Tumors 3\u003cbr\u003e\u003ci\u003eMark R. Gilbert and Edina Komlodi-Pasztor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Head and Neck and Thoracic Cancers 13\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2 Localized Head and Neck Cancer 15\u003cbr\u003e\u003ci\u003eEmrullah Yilmaz and Jessica L. Geiger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Recurrent and Metastatic Head and Neck Cancer 31\u003cbr\u003e\u003ci\u003eChloe Weidenbaum and Mike Gibson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Thyroid Cancers 39\u003cbr\u003e\u003ci\u003eKartik Sehgal and Jochen H. Lorch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Non-Small Cell Lung Cancer: Screening, Staging, and Stage I 51\u003cbr\u003e\u003ci\u003eRyan D. Gentzler and Linda W. Martin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Non-Small Cell Lung Cancer: Stages II and III 63\u003cbr\u003e\u003ci\u003eGregory Peter Kalemkerian, Kamya Sankar, and Angel Qin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Recurrent and Metastatic Non-Small Cell Lung Cancer 79\u003cbr\u003e\u003ci\u003eJulia Judd, J. Nicholas Bodor, and Hossein Borghaei\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Small Cell Lung Cancer 97\u003cbr\u003e\u003ci\u003eJyoti D. Patel and Husam Hafzah\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Mesothelioma 105\u003cbr\u003e\u003ci\u003eHarvey I. Pass, David Chen, and Jack Donaghue\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Breast Cancer 115\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10 DCIS and LCIS 117\u003cbr\u003e\u003ci\u003eAmanda Nash, Rita Mukhtar, and Shelley Hwang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Early-Stage ER\/PR –Positive, HER2-Negative Breast Cancer 129\u003cbr\u003e\u003ci\u003eWilliam J. Gradishar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 ER\/PR-Positive, HER2-Negative Metastatic Breast Cancer 139\u003cbr\u003e\u003ci\u003eSara Nunnery, Laura Kennedy, and Sonya Reid\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Early-Stage HER2-Positive Breast Cancer 151\u003cbr\u003e\u003ci\u003eErin Roesch and Jame Abraham\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 HER2-Positive Metastatic Breast Cancer 163\u003cbr\u003e\u003ci\u003eReshma L. Mahtani, Naomi G. Dempsey, and Ana Sandoval\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Early-Stage Triple-Negative Breast Cancer 179\u003cbr\u003e\u003ci\u003eTiffany A. Traina, Carlos dos Anjos, and Elaine Walsh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Triple-Negative Metastatic Breast Cancer 191\u003cbr\u003e\u003ci\u003eAzadeh Nasrazadani, Juan Gomez, and Adam Brufsky\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Inflammatory Breast Cancer – A Distinct Entity 201\u003cbr\u003e\u003ci\u003eMassimo Cristofanilli and Elena Vagia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Male Breast Cancer 213\u003cbr\u003e\u003ci\u003eLaura A. Huppert, Ozge Gumusay, Shreya Desai, and Hope S. Rugo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Breast Cancer in Pregnancy and Fertility Preservation 225\u003cbr\u003e\u003ci\u003eFedro A. Peccatori, Hatem Azim, and Matteo Lambertini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Gastrointestinal Cancers 233\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e20 Early-Stage Gastroesophageal Cancer and Precursor Lesions 235\u003cbr\u003e\u003ci\u003eYixing Jiang and Aaron Ciner\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Metastatic Esophagogastric Cancer 249\u003cbr\u003e\u003ci\u003eGeoffrey Y. Ku and David H. Ilson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Early-Stage Colon Cancer 255\u003cbr\u003e\u003ci\u003eJohn Krauss, Vaibhav Sahai, and Al B. Benson III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Early-Stage Rectal Cancer 267\u003cbr\u003e\u003ci\u003eHannah J. Roberts, Theodore Hong, and Aparna Parikh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Recurrent and Metastatic Colorectal Cancer 283\u003cbr\u003e\u003ci\u003eJoseph Heng and Blase Polite\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Pancreatic Adenocarcinoma 291\u003cbr\u003e\u003ci\u003eEvan Walker, Andrew Ko, and Margaret Tempero\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Hepatocellular Cancer 309\u003cbr\u003e\u003ci\u003ePedro Luiz Serrano Uson Junior and Mitesh Borad\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Biliary Tract Cancers 319\u003cbr\u003e\u003ci\u003eDavid B. Zhen and Vaibhav Sahai\u003c\/i\u003e\u003c\/p\u003e 28 Carcinoid and Neuroendocrine Tumors 327\u003cbr\u003e\u003ci\u003eMintallah Haider and Jonathan Strosberg\u003c\/i\u003e \u003cp\u003e29 Anal Cancer 343\u003cbr\u003e\u003ci\u003eAsad Mahmood and Rob Glynne-Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5 Genitourinary Cancers 359\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e30 Renal Cancer 361\u003cbr\u003e\u003ci\u003eJames L. Coggan, Alan Tan, and Timothy M. Kuzel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Bladder Cancer 375\u003cbr\u003e\u003ci\u003eRevathi Kollipara, Alan Tan, and Timothy M. Kuzel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Prostate Cancer: Screening, Surveillance, Prognostic Algorithms, and Independent Pathologic Predictive Parameters 389\u003cbr\u003e\u003ci\u003eEduardo Benzi and Thomas M. Wheeler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Early and Locally Advanced Prostate Cancer 399\u003cbr\u003e\u003ci\u003eJames Randall, Mohammad R. Siddiqui, Ashley Ross, and Sean Sachdev\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Metastatic Prostate Cancer 421\u003cbr\u003e\u003ci\u003ePriyanka Chablani, Natalie Reizine, and Walter Stadler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Germ Cell Tumors 437\u003cbr\u003e\u003ci\u003eHamid Emamekhoo, Syed A. Abutalib, and Timothy Gilligan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6 Skin Malignancies 453\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e36 Melanoma 455\u003cbr\u003e\u003ci\u003eAna M. Ciurea and Kim Margolin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Nonmelanoma Skin Cancers 477\u003cbr\u003e\u003ci\u003eChrysalyne D. Schmults and Danielle A. Parker\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 7 Gynecological Cancers 497\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e38 Ovarian Cancer: Primary Treatment and Approach to Recurrent Disease 499\u003cbr\u003e\u003ci\u003eRani Bansal, Don Dizon, and Martina Murphy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e39 Ovarian Cancer: Second-line Treatment Strategies 511\u003cbr\u003e\u003ci\u003eMaurie Markman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e40 Endometrial Cancer 523\u003cbr\u003e\u003ci\u003eMaurie Markman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 Cancer of the Cervix, Vulva, and Vagina 533\u003cbr\u003e\u003ci\u003eSabrina M. Bedell and Peter G. Rose\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Uncommon Gynecologic Cancers 549\u003cbr\u003e\u003ci\u003eMichael Frumovitz, Shannon Westin, and David M. Gershenson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 8 Sarcomas 565\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e43 Bone Sarcomas 567\u003cbr\u003e\u003ci\u003eNicole Larrier, William Eward, and Richard F. Riedel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e44 Soft Tissue Sarcomas 579\u003cbr\u003e\u003ci\u003eJeffrey Farma, Krisha Howell, and Margaret von Mehren\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 9 Hereditary Cancer Syndromes and Genetic Testing 595\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e45 Hereditary Cancer Syndromes 597\u003cbr\u003e\u003ci\u003eMary B. Daly\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e46 Hereditary Breast and Ovarian Cancer Syndromes 611\u003cbr\u003e\u003ci\u003eKristen Whitaker and Elias Obeid\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e47 Hereditary Gastrointestinal and Pancreatic Cancer Syndromes 625\u003cbr\u003e\u003ci\u003eKristen M. Shannon, Linda H. Rodgers-Fouche, and Daniel C. Chung\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 10 Special Issues in Oncology 637\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e48 Cancer of Unknown Primary 639\u003cbr\u003e\u003ci\u003eTony Greco\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e49 Anticoagulation in Cancer 651\u003cbr\u003e\u003ci\u003eJean Marie Connors\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e50 Identification and Management of Immunotherapy-Related Adverse Events in Oncology 663\u003cbr\u003e\u003ci\u003eOzge Gumusay, Laura A. Huppert, Dame Idossa, and Hope S. Rugo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e51 Geriatric Oncology 677\u003cbr\u003e\u003ci\u003eSukeshi Patel Arora and Efrat Dotan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e52 Palliative Medicine for Curable and Terminal Cancers 693\u003cbr\u003e\u003ci\u003eIsabelle Blanchard, Kavitha Jennifer Ramachandran, and Divya Gupta\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 709\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eSyed A. Abutalib, MD,\u003c\/b\u003e is Co-Director of Hematology and Stem Cell Transplantation and Clinical Director of NMDP\u003csup\u003e®\u003c\/sup\u003e Apheresis Center at the Midwest Branch of Cancer Treatment Centers of America, (CTCA), Part of City of Hope.  \u003c\/p\u003e\u003cp\u003e\u003cb\u003eMaurie Markman, MD,\u003c\/b\u003e is President of Medicine \u0026amp; Science, Cancer Treatment Centers of America, Part of City of Hope. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eAl B. Benson III, M.D FACP FASCO,\u003c\/b\u003e is a Professor of Medicine in the Division of Hematology\/Oncology at Northwestern University’s Feinberg School of Medicine in Chicago, Illinois, and the Associate Director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center.  \u003c\/p\u003e\u003cp\u003e\u003cb\u003eHope S. Rugo, MD, FASCO,\u003c\/b\u003e is Director of Breast Oncology and Clinical Trials Education and a Professor of Medicine at the University of California San Francisco Comprehensive Cancer Center.   \u003c\/p\u003e\u003cp\u003e\u003cb\u003eNew edition covering the specialties of hematology, oncology and cellular therapy, now in two volumes\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003e\u003ci\u003eCancer Consult: Expertise in Clinical Practice, Volume 1: Solid Tumors \u0026amp; Supportive Care, Second Edition\u003c\/i\u003e includes hundreds of answers to practice-based questions covering the new principles of diagnosis, classification, staging, treatment, and outcomes in the rapidly advancing field of cancer. This textbook series also provides expert guidance in the areas of cancer-related uncertainties and controversies, including experience-based discussions. The book’s smaller size allows for easy access during medical rounds. This volume also includes:  \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eUp-to-date, clinically relevant information on the very latest topics such as molecular techniques, targeted therapies, immunotherapy, cellular therapy and translational cancer research\u003c\/li\u003e \u003cli\u003eSections on head, neck, thoracic, breast, GI, genitourinary, skin, gynecological and hereditary cancers, amongst other topics\u003c\/li\u003e \u003cli\u003eStreamlined, engaging content to make finding information easier and less time consuming for the reader\u003c\/li\u003e \u003cli\u003eConcise and practical expert perspectives that reference key studies\u003c\/li\u003e \u003cli\u003eReferences to the latest NCCN, ESMO, ASCO, and other national guidelines\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWith its powerful focus on pragmatic clinical diagnostic, therapeutic and prognostic approaches, \u003ci\u003eCancer Consult: Expertise in Clinical Practice, Volume 1: Solid Tumors \u0026amp; Supportive Care, Second Edition\u003c\/i\u003e will help keep hematology, oncology and cellular therapy practitioners up-to-date, bridging the gaps between journal and reference literature, conferences, and their existing knowledge base. It also offers clinicians, trainees, and fellows an excellent opportunity to enhance their preparation for the ABIM, hematology and oncology fellowship and recertification exams.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47988880900325,"sku":"NP9781119823735","price":150.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119823735.jpg?v=1761781898","url":"https:\/\/k12savings.com\/products\/cancer-consult-expertise-in-clinical-practice-volume-1-isbn-9781119823735","provider":"K12savings","version":"1.0","type":"link"}